Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances

ORAGENICS INC

Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.
Submitted Investigator's Brochure for Phase IIa trial in Australia; trial listed on ClinicalTrials.gov; awaiting HREC approval.
Partnered with BRAINBox Solutions to combine intranasal ONP-002 with diagnostic biomarkers for personalized concussion care.
Upcoming milestones: HREC approval and first patient enrollment in Q2 2025; Phase IIa enrollment completion by Q4 2025.
Simplified capital structure by converting all preferred shares to common; annual meeting set for May 2, 2025.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001641172-25-000855
form_type: 8-K
ticker: OGEN
cik: 0001174940
company_name: ORAGENICS INC
filed_at: 2025-03-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.088236+00:00
generated_at: 2026-05-24T03:41:55.235296+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001641172-25-000855
json_url: https://secwatch.observer/filing/0001641172-25-000855.json
markdown_url: https://secwatch.observer/filing/0001641172-25-000855.md
text_url: https://secwatch.observer/filing/0001641172-25-000855.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/0001641172-25-000855-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001641172-25-000855

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.